Teva Launches AHZANTIVE Biosimilar in Four European Markets in May 2026
TEVA•Teva launched AHZANTIVE (aflibercept), its EMA-approved biosimilar to Eylea, in May 2026 across France, Germany, Spain and the Netherlands, expanding its ophthalmology portfolio. The move builds on a semi-exclusive commercialization agreement with Klinge Biopharma and Formycon and targets further European rollouts later this year.
1. Launch Details
In May 2026 Teva began commercial launch of AHZANTIVE pre-filled syringes across France, Germany, Spain and the Netherlands, marking its first ophthalmology biosimilar rollout in these markets. The launch leverages a semi-exclusive partnership with Klinge Biopharma and Formycon for major parts of Europe and Israel.
2. Product Profile and Indications
AHZANTIVE is an EMA-approved biosimilar to Eylea, indicated for neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization and macular edema following retinal vein occlusion. Clinical comparability studies demonstrate equivalent efficacy, safety and immunogenicity to the reference product.
3. Strategic Impact
The launch expands Teva’s biosimilars portfolio to 11 marketed products and supports its Pivot to Growth strategy by strengthening its presence in ophthalmology. Teva plans additional market introductions later in 2026 to broaden access to high-quality biologic therapies across Europe.
